Advertisement
Research Article

Aripiprazole in the Maintenance Treatment of Bipolar Disorder: A Critical Review of the Evidence and Its Dissemination into the Scientific Literature

  • Alexander C. Tsai equal contributor mail,

    equal contributor Contributed equally to this work with: Alexander C. Tsai, Nicholas Z. Rosenlicht

    nicholas.rosenlicht@ucsf.edu

    Affiliation: Robert Wood Johnson Health and Society Scholars Program, Harvard University, Cambridge, Massachusetts, United States of America

    X
  • Nicholas Z. Rosenlicht equal contributor,

    equal contributor Contributed equally to this work with: Alexander C. Tsai, Nicholas Z. Rosenlicht

    Affiliation: Department of Psychiatry, University of California at San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, California, United States of America

    X
  • Jon N. Jureidini,

    Affiliation: Discipline of Psychiatry, University of Adelaide, Adelaide, South Australia, Australia

    X
  • Peter I. Parry,

    Affiliation: Child and Adolescent Mental Health Service, Division of Mental Health, Flinders University, Adelaide, South Australia, Australia

    X
  • Glen I. Spielmans,

    Affiliation: Department of Psychology, Metropolitan State University, St. Paul, Minnesota, United States of America

    X
  • David Healy

    Affiliation: Department of Psychological Medicine, Cardiff University, Cardiff, Wales, United Kingdom

    X
  • Published: May 03, 2011
  • DOI: 10.1371/journal.pmed.1000434

Reader Comments (2)

Post a new comment on this article

Media coverage of this article

Posted by plosmedicine on 12 May 2011 at 16:28 GMT

We thought readers might be interested in the media coverage that this paper received, including the following:

LA Times: http://articles.latimes.c...

CNN: http://edition.cnn.com/20...

Pharmalot: http://www.pharmalot.com/...

The CNN coverage includes a response from a US Food and Drug Administration spokesperson saying that the agency will review this study. The Pharmalot article contains comments from a Bristol-Myers Squibb spokeswoman and from author Nicholas Rosenlicht.

No competing interests declared.